

Applicants: Philip O. Livingston and Friedhelm Helling  
Serial No.: 08/477,097  
Filed : June 7, 1995  
Page 2

A marked-up version of the amended claims, wherein the deleted material is in brackets and the inserted material is underlined, is attached hereto as Exhibit A.

--78. (Amended) A composition which comprises:

a) a conjugate of i) a GM2 or GD2 ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion comprising a sphingosine base, to ii) Keyhole Limpet Hemocyanin, comprising an  $\epsilon$ -aminolysyl group;

b) a saponin derivable from the bark of a Quillaja saponaria Molina tree; and

c) a pharmaceutically acceptable carrier;

the relative amounts of such conjugate and such saponin being effective to stimulate or enhance antibody production in a subject,

wherein in the conjugate the ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin through a C-4 carbon of the sphingosine base of the ceramide portion of the ganglioside derivative to the  $\epsilon$ -aminolysyl group of Keyhole Limpet Hemocyanin, wherein the C-4 carbon is present in a  $\text{CH}_2$  group. --

Applicants: Philip O. Livingston and Friedhelm Helling  
Serial No.: 08/477,097  
Filed : June 7, 1995

Page 3

--92. (Amended) A method of stimulating or enhancing antibody production in a subject which comprises administering to the subject an effective amount of a composition which comprises:

a) a conjugate of i) a GM2 or GD2 ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion comprising a sphingosine base, to ii) Keyhole Limpet Hemocyanin, comprising an  $\epsilon$ -aminolysyl group;

K 2  
b) a saponin derivable from the bark of a Quillaja saponaria Molina tree; and

c) a pharmaceutically acceptable carrier;

the relative amounts of such conjugate and such saponin being effective to stimulate or enhance antibody production in the subject,

wherein in the conjugate the ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin through a C-4 carbon of the sphingosine base of the ceramide portion of the ganglioside derivative to the  $\epsilon$ -aminolysyl group of Keyhole Limpet Hemocyanin, wherein the C-4 carbon is present in a  $\text{CH}_2$  group, so as to thereby stimulate or enhance antibody production in the subject. --

Applicants: Philip O. Livingston and Friedhelm Helling  
Serial No.: 08/477,097  
Filed : June 7, 1995

Page 4

--94. (Three Times Amended) A method of treating a cancer in a subject which comprises administering to the subject an effective cancer treating amount of a composition which comprises:

a) a conjugate of i) a GM2 or GD2 ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion comprising a sphingosine base, to ii) Keyhole Limpet Hemocyanin, comprising an  $\epsilon$ -aminolysyl group;

b) a saponin derivable from the bark of a Quillaja saponaria Molina tree; and

c) a pharmaceutically acceptable carrier;

the relative amounts of such conjugate and such saponin being effective to stimulate or enhance antibody production in the subject,

wherein in the conjugate the ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin through a C-4 carbon of the sphingosine base of the ceramide portion of the ganglioside derivative to the  $\epsilon$ -aminolysyl group of Keyhole Limpet Hemocyanin, wherein the C-4 carbon is present in a  $\text{CH}_2$  group, so as to thereby treat the cancer in the subject.--

Please cancel claim 79 without prejudice.